JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

486.19 -1.57

Buy Sell

Overview

Share price change

24h

Current

Min

484.9

Max

490.92

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+39.64% upside

Dividends
By Dow Jones
Next Earnings	25 lut 2026

Market Stats
By TradingEconomics
Market Cap	2.1B 11B
Previous open	487.76
Previous close	486.19

News Sentiment

By Acuity

28%

72%

70 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 sty 2026, 20:14 UTC

Acquisitions, Mergers, Takeovers

Reddy Ice to Buy Arctic Glacier, DOJ Requires Certain Divestitures

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30 sty 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30 sty 2026, 23:41 UTC

Market Talk

Deckers Outdoor Seen as Undervalued -- Market Talk

30 sty 2026, 23:12 UTC

Acquisitions, Mergers, Takeovers

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30 sty 2026, 22:20 UTC

Earnings

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30 sty 2026, 22:10 UTC

Market Talk

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30 sty 2026, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

30 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 sty 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

30 sty 2026, 21:42 UTC

Earnings

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 sty 2026, 21:36 UTC

Earnings

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30 sty 2026, 21:33 UTC

Earnings

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30 sty 2026, 20:42 UTC

Earnings

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 sty 2026, 20:37 UTC

Acquisitions, Mergers, Takeovers

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

30 sty 2026, 20:20 UTC

Market Talk

Oil Posts Weekly Gains on U.S.-Iran Tensions -- Market Talk

30 sty 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather-Driven Demand -- Market Talk

30 sty 2026, 19:52 UTC

Earnings

Visa and Amex Results Point to a Strong Holiday Season for Retailers -- Barrons.com

30 sty 2026, 19:29 UTC

Market Talk

Earnings

KLA Guidance Only 'Tepid' as Memory Rally Favors Peers -- Market Talk

30 sty 2026, 19:09 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 sty 2026, 19:09 UTC

Market Talk

Next Canadian Inflation Release Pushed Back a Day to Not Clash With Holiday -- Market Talk

30 sty 2026, 19:07 UTC

Market Talk

Canada Performing Well Below Economic Potential -- Market Talk

30 sty 2026, 18:46 UTC

Earnings

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

30 sty 2026, 18:34 UTC

Earnings

Exxon, Chevron Post Slimmest Annual Profits Since 2021 -- 2nd Update

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

39.64% upside

12 Months Forecast

Average 690.8 USD 39.64%

High 964 USD

Low 533 USD

Based on 13 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

70 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.